Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Herbert J. Zeh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2017-1934; OpenAlex author ID A5073859061, A5113209796; NIH RePORTER profile ID 7605187. Sources: ClinicalTrials.gov.

Their work

Papers
84 (first author 4, last author 8)
Trials
3 (principal investigator on 3)
Grants
1
Labs led
2
Collaborators
192
Papers, trials and grants by year

2006: 1 trial · 2007: none · 2008: 1 trial · 2009: none · 2010: 1 trial · 2011: 2 papers · 2012: 2 papers · 2013: 5 papers · 2014: 5 papers · 2015: 5 papers · 2016: 5 papers · 2017: 8 papers · 2018: 11 papers, 1 grant · 2019: 8 papers · 2020: 9 papers · 2021: 8 papers · 2022: 3 papers · 2023: 4 papers · 2024: 2 papers · 2025: 5 papers · 2026: 2 papers

Papers 50 of 84

  1. Pretreatment CA19-9 Predicts Survival in Pancreatic Cancer With Optimal Response to Neoadjuvant Therapy. Co-author DOI 10.1002/jso.70179↗
  2. Combined Association of Time to Treatment, Guideline Concordance, and Neighborhood Vulnerability with Localized Colon Cancer, Non-small-cell Lung Cancer, and P… Co-author DOI 10.1245/s10434-026-19760-5↗
  3. Form Follows Function: A New Paradigm of Pancreatic Cancer Progression Co-author DOI 10.1101/2025.08.12.667175↗
  4. Post-operative patterns of failure and outcomes reveal opportunities to optimize treatment of recurrent pancreatic cancer Co-author DOI 10.1101/2025.11.08.25339815↗
  5. AGER-dependent macropinocytosis drives resistance to KRAS-G12D-targeted therapy in advanced pancreatic cancer. Co-author DOI 10.1126/scitranslmed.adp4986↗
  6. Presurgical Ablative Radiation Is Associated with Local Control and Immune Response in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-3582↗
  7. Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: An American Mult… Co-author DOI 10.1245/s10434-025-16916-7↗
  8. Minimally invasive pancreaticoduodenectomy: A favorable approach for frail patients with pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.12.022↗
  9. Delta Radiomic Features Predict Resection Margin Status and Overall Survival in Neoadjuvant-Treated Pancreatic Cancer Patients. Co-author DOI 10.1245/s10434-023-14805-5↗
  10. Factors associated with failure to operate and its impact on survival in early-stage pancreatic cancer. Co-author DOI 10.1002/jso.27357↗
  11. Implications of the interaction between travel burden and area deprivation for patients with pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2023.06.013↗
  12. A Combined DNA/RNA-based Next-Generation Sequencing Platform to Improve the Classification of Pancreatic Cysts and Early Detection of Pancreatic Cancer Arising… Co-author DOI 10.1097/sla.0000000000005904↗
  13. Hospital Designations and Their Impact on Guideline-Concordant Care and Survival in Pancreatic Cancer. Do They Matter? Co-author DOI 10.1245/s10434-023-13308-7↗
  14. Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2022.18355↗
  15. Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict … Co-author DOI 10.1016/j.cgh.2020.11.041↗
  16. Ablative Radiation Therapy in Oligometastatic Pancreatic Cancer to Delay Polyprogression, Limit Chemotherapy, and Improve Outcomes. Co-author DOI 10.1016/j.ijrobp.2022.07.019↗
  17. Current Controversies in Neoadjuvant Therapy for Pancreatic Cancer. First author DOI 10.1016/j.soc.2021.06.010↗
  18. Cell death in pancreatic cancer: from pathogenesis to therapy. First author DOI 10.1038/s41575-021-00486-6↗
  19. Regulation and function of autophagy in pancreatic cancer. Co-author DOI 10.1080/15548627.2020.1847462↗
  20. SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma. Co-author DOI 10.1111/cts.13029↗
  21. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2019-320441↗
  22. Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case-Control Matched Analysis. Co-author DOI 10.1245/s10434-020-09391-9↗
  23. A Pancreatic Cancer Multidisciplinary Clinic Eliminates Socioeconomic Disparities in Treatment and Improves Survival. Co-author DOI 10.1245/s10434-021-09594-8↗
  24. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10175-y↗
  25. Targeting TAM to Tame Pancreatic Cancer. Co-author DOI 10.1007/s11523-020-00751-9↗
  26. A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Co-author DOI 10.1158/1078-0432.ccr-19-4042↗
  27. Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-08094-0↗
  28. Clinicopathologic Features and Outcomes of Early-Onset Pancreatic Adenocarcinoma in the United States. Co-author DOI 10.1245/s10434-019-08096-y↗
  29. Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-019-08156-3↗
  30. Correction to: Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08249-4↗
  31. CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08468-9↗
  32. SMAD4 Loss is Associated with Response to Neoadjuvant Chemotherapy with Hydroxychloroquine in Patients with Pancreatic Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-125334/v1↗
  33. Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2214/ajr.19.21152↗
  34. The platelet NLRP3 inflammasome is upregulated in a murine model of pancreatic cancer and promotes platelet aggregation and tumor growth. Co-author DOI 10.1007/s00277-019-03692-0↗
  35. Can post-hoc video review of robotic pancreaticoduodenectomy predict portal/superior mesenteric vein margin status in pancreatic adenocarcinoma? Co-author DOI 10.1016/j.hpb.2018.10.012↗
  36. Pancreatic Cancer Presenting as a Pancreatic Duct Disruption. First author DOI 10.1155/2019/6381249↗
  37. Prolactin Promotes Fibrosis and Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-18-3064↗
  38. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pa… Co-author DOI 10.1158/1078-0432.ccr-18-2992↗
  39. Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. Co-author DOI 10.1200/jco.19.00946↗
  40. Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy Followed by Surgical Resection. Last author DOI 10.1245/s10434-018-07148-z↗
  41. Sociodemographic Disparities in the Receipt of Adjuvant Chemotherapy Among Patients With Resected Stage I-III Pancreatic Adenocarcinoma. Co-author DOI 10.6004/jnccn.2019.7322↗
  42. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.31628↗
  43. Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer. How I do It. Co-author DOI 10.1007/s11605-018-3894-7↗
  44. Autophagy Inhibition in Pancreatic Adenocarcinoma. First author DOI 10.1016/j.clcc.2017.10.013↗
  45. Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resecta… Co-author DOI 10.1016/j.prro.2017.10.001↗
  46. Overweight or Obese Individuals at Eighteen Years of Age Develop Pancreatic Adenocarcinoma at a Significantly Earlier Age. Co-author DOI 10.1155/2018/2380596↗
  47. Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps. Last author DOI 10.1186/s12885-018-4584-2↗
  48. Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer. Co-author DOI 10.1186/s12967-018-1562-z↗
  49. Health Disparities Impact Expected Treatment of Pancreatic Ductal Adenocarcinoma Nationally. Co-author DOI 10.1245/s10434-018-6487-5↗
  50. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time. Co-author DOI 10.1245/s10434-018-6521-7↗

Trials 3

  1. Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas Principal investigator NCT01128296↗
  2. Safety Study of Modified Vaccinia Virus to Cancer Principal investigator NCT00574977↗
  3. Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer Principal investigator NCT00557492↗

Grants 1

  1. Pancreatic Ductal Adenocarcinoma is a disease of constitutive autophagy R01CA181450↗

Closest collaborators

The 25 strongest of 192 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Amer H. Zureikat · 33 shared papers, 2012–2026 · strength 3.05
  2. Melissa Ellen Hogg · 27 shared papers, 2014–2026 · strength 2.73
  3. Nathan Bahary · 33 shared papers, 2011–2022 · strength 2.62
  4. Patricio Marcelo Polanco · 12 shared papers, 2020–2026 · strength 2.31
  5. Brian A. Boone · 22 shared papers, 2013–2026 · strength 2.27
  6. Michael T. Lotze · 17 shared papers, 1 shared grant, 2013–2021 · strength 1.73
  7. Aatur Dilip Singhi · 19 shared papers, 2014–2022 · strength 1.60
  8. Adam Charles Yopp · 7 shared papers, 2020–2025 · strength 1.22
  9. Matthew R. Porembka · 7 shared papers, 2020–2025 · strength 1.20
  10. Daolin Tang · 11 shared papers, 2013–2025 · strength 1.11
  11. Todd Anthony Aguilera · 6 shared papers, 2019–2025 · strength 0.93
  12. Rui Kang · 7 shared papers, 2014–2025 · strength 0.88
  13. Alessandro Paniccia · 6 shared papers, 2021–2026 · strength 0.87
  14. Gilbert Zvikomborero Murimwa · 4 shared papers, 2023–2026 · strength 0.86
  15. Amr I. Al Abbas · 7 shared papers, 2018–2024 · strength 0.85
  16. Caroline J. Rieser · 7 shared papers, 2018–2025 · strength 0.81
  17. David L. Bartlett · 12 shared papers, 2011–2021 · strength 0.77
  18. Ahmed M. Elamir · 4 shared papers, 2022–2025 · strength 0.70
  19. Asmita Chopra · 4 shared papers, 2021–2026 · strength 0.67
  20. Sam C. Wang · 4 shared papers, 2020–2024 · strength 0.66
  21. Nina Niu Sanford · 4 shared papers, 2019–2025 · strength 0.64
  22. Emile Farah · 3 shared papers, 2024–2026 · strength 0.63
  23. Ahmad B. Hamad · 6 shared papers, 2017–2020 · strength 0.59
  24. Muhammad Shaalan Beg · 4 shared papers, 2019–2025 · strength 0.54
  25. Syed Mohammad Ali Kazmi · 3 shared papers, 2022–2025 · strength 0.54

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.